Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cabaletta Bio, Inc.

Get SEC filing alerts via email and in your feed for Cabaletta Bio, Inc.

CABA

Cabaletta Bio, Inc.

About Cabaletta Bio, Inc.

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies targeting autoimmune diseases. Its proprietary CABA platform includes CARTA and CAART strategies to reset or eliminate disease-causing B cells. The company’s lead candidate, rese-cel, aims to provide durable, potentially curative responses across multiple autoimmune conditions. It collaborates with academic and manufacturing partners to advance innovative, scalable therapies with a focus on safety and broad patient impact.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cabaletta Bio, Inc.

1
1
Cabaletta Bio, Inc. Cabaletta Bio Reports $43.5 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Cabaletta Bio, Inc. Cabaletta Bio Reports $167.9 Million Net Loss and Advances Autoimmune Disease Therapies

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Cabaletta Bio, Inc. Cabaletta Bio Reports 41% Increase in Operating Expenses and $44.9 Million Net Loss for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cabaletta Bio, Inc. Cabaletta Bio Reports $45.1 Million Net Loss in Q2 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cabaletta Bio, Inc. Cabaletta Bio Reports $35.9 Million Net Loss in Q1 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cabaletta Bio, Inc. Cabaletta Bio Reports $115.9 Million Net Loss for 2024, Highlights FDA Approvals and Clinical Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Cabaletta Bio, Inc. Cabaletta Bio Reports Increased R&D Expenses and Net Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments